Prelude Capital Management’s Anika Therapeutics ANIK Stock Holding History

Prelude Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,490	Closed	-$43K	–	1935
2020 Q1	$43K	Sell	1,490 -2,332	-61%	-$94.3K	﹤0.01%	790
2019 Q4	$198K	Buy	+3,822	New	+$222K	0.01%	859
2019 Q1	–	Sell	-4,865	Closed	-$164K	–	1741
2018 Q4	$164K	Buy	+4,865	New	+$176K	0.01%	791
2018 Q3	–	Sell	-3,207	Closed	-$103K	–	1710
2018 Q2	$103K	Buy	+3,207	New	+$132K	0.01%	906
2016 Q4	–	Sell	-1,067	Closed	-$51K	–	1527
2016 Q3	$51K	Buy	+1,067	New	+$52.7K	0.01%	1031
2015 Q2	–	Sell	-4,600	Closed	-$189K	–	1672
2015 Q1	$189K	Buy	+4,600	New	+$186K	0.03%	676
2014 Q3	–	Sell	-2,769	Closed	-$128K	–	1844
2014 Q2	$128K	Buy	2,769 +800	+41%	+$35.6K	0.02%	990
2014 Q1	$81K	Buy	+1,969	New	+$73.2K	0.01%	1107

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Prelude Capital Management's ANIK Position: Q2 2020 in Review

Prelude Capital Management sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 1,490 shares — an estimated $43K sold.

Prelude Capital Management first reported a position in ANIK in Q1 2014 and held it in 8 quarters. The position peaked at $198K in Q4 2019. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

Prelude Capital Management reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
Prelude Capital Management sold 1,490 Anika Therapeutics shares in Q2 2020, an estimated $43K.
Prelude Capital Management first reported a position in Anika Therapeutics in Q1 2014 and held it in 8 quarters.
Prelude Capital Management's Anika Therapeutics position peaked at $198K in Q4 2019.
158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Prelude Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.